11:44:24 EDT Mon 29 May 2023
Enter Symbol
or Name

Login ID:

Cannabis Summary for Sept. 22, 2022

2022-09-22 20:09 ET - Market Summary

This item is part of Stockwatch's value added news feed and is only available to Stockwatch subscribers.

Here is a sample of this item:

by Stockwatch Business Reporter

The S&P/TSX Cannabis Index lost 1.88 to 37.00, while the CSE Composite Index lost 6.17 to 261.75. After a delay of nearly a year, the government of Canada has finally launched a review of the Cannabis Act. The mandatory yet overdue review was supposed to start last October, three years after legalization.

The Cannabis Act established purchase and possession limits, safety standards for cultivation and sales, and restrictions on youth access -- all with the provision, set out clearly in Section 151, that the government carry out a review three years after enactment. Specifically, the government must review the effects of legalization on public health, youth consumption, indigenous communities and home cultivation. The act also requires a presentation of the review's findings to Parliament within 18 months.

In a joint announcement this morning, Health Minister Jean-Yves Duclos and Mental Health and Addictions Minister Carolyn Bennett formally launched the long-awaited review. They added that they will also expand its scope to include socio-economic and environmental factors, the effects of recreational legalization on the medical market, and progress in eroding the black market. "Through this useful, inclusive and evidence-driven review, we will strengthen the Act so that it meets the needs of all Canadians while continuing to displace the illicit market," declared Mr. Duclos.

The remainder is available to Stockwatch subscribers.
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

© 2023 Canjex Publishing Ltd. All rights reserved.

Reader Comments - Comments are open to paying subscribers of Stockwatch and unmoderated, although libelous remarks, obscene language and impersonations may be deleted. Opinions expressed do not necessarily reflect the views of Stockwatch.
For information regarding Canadian libel law, please view the University of Ottawa's FAQ regarding Defamation and SLAPPs.